Section Arrow
ILMN.NASDAQ
- Illumina
Quotes are at least 15-min delayed:2025/07/02 20:22 EDT
Last
 100.34
+2.19 (+2.23%)
Day High 
100.96 
Prev. Close
98.15 
1-M High
100.15 
Volume 
2.17M 
Bid
100
Ask
101
Day Low
97.925 
Open
98.15 
1-M Low
78.79 
Market Cap 
15.54B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 92.81 
20-SMA 89.19 
50-SMA 83.17 
52-W High 156.66 
52-W Low 68.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.08/4.81
Enterprise Value
17.58B
Balance Sheet
Book Value Per Share
14.96
Cash Flow
Cash Flow Yield
0.06
Income Statement
Total Revenue
3.33B
Operating Revenue Per Share
28.18
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NEOGNeogen Corp5.23+0.15+2.95%879PE
BIAFbioAffinity Technologies0.29+0.0265+10.06%-- 
DHRDanaher Corp202.5+1.4+0.70%38.97PE
OPKOPKO Health1.34+0.01+0.75%-- 
TMOThermo Fisher Scientific427.76+6.29+1.49%24.72PE
Quotes are at least 15-min delayed:2025/07/02 20:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.